跳转到主内容

非常抱歉,我们不完全支持您的浏览器。如果您可以选择,请升级到较新版本或使用 Mozilla Firefox、Microsoft Edge、Google Chrome 或 Safari 14 或更高版本。如果您无法进行此操作且需要支持,请将您的反馈发送给我们。

Elsevier
通过我们出版

Choosing the right AI solution for your R&D workflow and AI ecosystem

Exploring the options for AI in R&D, and why the best choices may differ by industry.

What are the options for adopting AI in R&D?

When adopting AI in R&D, leaders need to decide whether to build internally, buy solutions externally, or some combination of the two. This often depends on your industry and the size of the organization, as many companies lack the infrastructure to move AI fully from pilot to production. However, other, more mature industries may choose to partner with trusted vendors to integrate data into their in-house models and tools. 

Regardless of the choice, AI is only able to drive real impact in R&D if the solution is the best fit for your company’s use case. 

When should you buy AI solutions for R&D?

Commercial AI platforms often offer more validated functionality, domain expertise accumulated across multiple customer deployments and ongoing development investment. They also reduce time-to-value: 64% of organizations that realize value from AI do so within six monthsopens in new tab/window — a timeline that custom builds will struggle to achieve. 

However, that doesn’t mean organizations will see instant value. If you’re buying an AI tool, you are also buying the vendor’s data scope and definition of the workflow. It’s crucial that you scrutinize the corpus behind the tool, as well as its ability to truly provide your teams with productive responses and traceable results. 

Ultimately, buying is often the best choice when the bottleneck is external knowledge rather than internal data: literature discovery and evidence synthesis, horizon scanning, competitive and IP intelligence, regulatory precedent searching, materials and property lookups.

When should you develop AI solutions in house?

For large companies with mature data science functions, developing AI in-house enables them to build their own infrastructure against their own data. This gives you complete control of IP and — crucially — lets you encode assets nobody else has: assay results, failed reactions, formulation history, process parameters and decades of legacy experimental records. 

This is usually not the best fit at smaller companies faced with time and talent shortages — development is a burden that many companies can’t handle. It’s critical to ask who owns the model in three years, and who retrains it. Also, much of the data R&D organizations hold is siloed, inconsistently formatted and thin on metadata, and structuring it with ontologies and taxonomies is specialized work that requires investment. 

However, if the model itself is a source of competitive advantage — and you already have AI-ready data and significant data science expertise in-house — this route could bear significant fruit.

How can connectors help integrate scientific data into your AI ecosystem?

Connectors enable R&D organizations to work with trusted partners to embed relevant scientific data directly into their existing AI ecosystem. With connectors, R&D teams can connect to multiple data sources through the models they already use every day.

The best connectors do some of the tedious translation work for you: they recognize that different names and identifiers point to the same compound or entity, reconcile mismatched units and vocabularies, and hand back clean, structured results ready for analysis.

Connectors are valuable for teams that use several AI tools, work under regulatory scrutiny, or lack the data-engineering capacity to maintain custom integrations.

Why general AI solutions aren’t always the right answer for R&D

General-purpose assistants are impressive and widely available, but for scientific decision-making, they are frequently the wrong tool — and researchers know it. In Elsevier's research, 84% of researchers said they have used AI tools in their work, but only 22% said they trust the tools available to them, and 86% said AI can cause critical errors. 

That gap has specific, technical causes. 

The corpus often stops at the abstract. Most peer-reviewed literature is licensed, so general tools reason over what is openly accessible. This means quite a bit can be missed. Adverse events, mutations, cell processes and negative results are among the details least likely to surface in an abstract. 

Often, scientific language defeats general retrieval. For example, the same gene may appear as PSEN1, PSNL1 or Presenilin-1. "Heart attack" and "myocardial infarction" are the same event. Without rich ontologies and controlled vocabularies to harmonize synonyms, or tools to help researchers dig deeper into the context around a claim, a search that looks successful can silently miss the evidence that mattered — and you cannot tell from the answer alone.

What are the benefits of purpose-built AI tools for R&D?

Purpose-built tools narrow the problem deliberately with a curated data foundation and outputs designed to be checked rather than merely read. Ideally, responses are drawn from full text, not just abstracts, with citations and direct links to the original passage, so validating an answer takes seconds rather than an afternoon. Users are able to stay in control, digging deeper into the scientific claims and understanding what is known and what is unknown, not just taking responses at face value.

The right tool can assist with specialist tasks generic tools can't reach. Examples include predictive retrosynthesis for route planning, regulatory precedent searching across FDA and EMA data, biomedical evidence retrieval including conference abstracts, preprints and trial registries, vetted engineering property data and analysis of your own uploaded documents alongside the published record. 

All these benefits combine to create tangible improvements to how R&D teams operate, including less time assembling evidence and more time interpreting it, fewer duplicated experiments, earlier and cheaper decisions, faster regulatory readiness and sharper competitive and IP intelligence. And, perhaps most crucially for R&D leaders, AI adoption that actually sticks.

Why Elsevier develops AI for R&D

Elsevier’s AI solutions consider the needs not just of the researcher, but of the larger R&D organization. R&D teams don’t just need responses faster — they need the ability to turn evidence into key decisions, staying ahead of the competition while not making expensive mistakes. 

Elsevier has is well-positioned to help any organization, whether they are looking to buy, build or partner. LeapSpace, Elsevier's research-grade AI workspace, generates its responses using peer-reviewed full-text content from Elsevier and selected full-text content from content partners, alongside Scopus abstracts and metadata. Elsevier Datasets and Connectors enable organizations to embed trusted scientific information into their existing workflow and ecosystem. Organizations can also partner with Elsevier to develop solutions to bring Elsevier's trusted data to where their R&D teams need it the most.

Explore Elsevier's advanced data solutions supporting AI in R&D, including datasets, connectors and more

Young man working as software developer, coding on computer in modern office